Neurogenic rosacea: a trial plans to test microbiota transplantation, with no results available

A gut-based hypothesis for skin symptoms

The abstract describes neurogenic rosacea as a specific form of rosacea involving persistent facial redness, flushing, burning and tingling. According to the authors, it often responds poorly to conventional treatments.

The researchers propose examining the role of the gut microbiota. Their hypothesis is that changing this ecosystem could affect the mechanisms involved in the symptoms. However, this biological plausibility is not evidence that microbiota transplantation improves the condition.

What the trial plans to compare

The planned study is exploratory, single-center, randomized and double-blind, with a placebo group. The 60 participants are to be divided equally between fecal microbiota capsules and placebo capsules, administered for three consecutive weeks. The planned follow-up is 12 weeks.

The primary outcome is the proportion of participants achieving success on the CEA score at week 12. The protocol defines success as a score of 0 or 1, or a decrease of at least two grades from baseline.

Secondary outcomes include flushing severity, symptoms, quality of life, psychological status, an objective redness index and safety. Exploratory analyses will also examine gut microbiota composition, metabolites present in stool and serum, and cytokines related to neurovascular mechanisms.

A protocol is not yet a basis for choosing a treatment

The comparison with a placebo is intended to assess whether the intervention provides a benefit beyond that observed in the control group. But the abstract presents no results: no measured improvement, no difference between groups and no observed adverse effects.

Even if favorable results were subsequently reported, the exploratory design, sample size of 60 patients and single-center setting would limit their scope. The biological analyses could shed light on a proposed mechanism, but would not replace evidence of a benefit for symptoms.

At this stage, this publication therefore describes a research question, not a new validated treatment option.

What we can take away

The value of this protocol lies in testing a hypothesis against a placebo. It does not yet support the conclusion that microbiota transplantation relieves neurogenic rosacea.